influenza a

CEF8, Influenza Virus NP (383-391), is an influenza A virus nucleoprotein containing residues 383 to 391, and it is the most important HLA-B*2705-restricted epitope in the nucleoprotein of influenza A viruses, associated with escape from cytotoxic T lymphocytes-mediated immunity. [HLA-B*3501 restricted influenza virus nucleoprotein epitope (383-391).]

Influenza HA 126-138 acetate is a influenza virus hemagglutinin (HA) peptide acetate comprising amino acids 126-138. Influenza HA 126-138 acetate induces thymic and peripheral T-cell apoptosis.

Influenza HA (110-119) acetate is the 110-119 fragment of influenza virus hemagglutinin that can stimulate Treg cells proliferation[1][2].

Influenza NP (311-325) is a biologically active peptide consisting of amino acids 311 to 325 from the influenza virus nucleoprotein (NP). As a bona fide MHC class II-restricted epitope, it is critical for studying host immune responses during viral infection, inducing robust gamma interferon (IFN-gamma) production in intracellular cytokine assays without stimulating CD8 T-cells in mice. The presence of Glutamine (Q) or Glutamic acid (E) at the N-terminus can lead to spontaneous formation of Pyroglutamyl (pGlu) peptides, enhancing peptide stability against gastrointestinal proteases. These peptides are considered a normal variant and included in peptide purity measurements in HPLC analysis.

NS2 (114-121), Influenza, is a fragment derived from the nonstructural protein 2 (NS2) of the influenza virus, serving as an epitope for influenza research and useful for studying CD8+ cytotoxic T lymphocyte (CTL) responses in antiviral immunity.

Influenza HA (110-119) refers to a specific fragment (110-119) derived from the hemagglutinin protein of the influenza virus. This fragment has the ability to induce the proliferation of Treg cells.

This peptide is an H2-Db-restricted epitope from the Influenza A/PR/8/34 nucleoprotein.

Partial antigenic glycoprotein

This peptide is a H-2Kd-restricted epitope from Influenza nucleoprotein (147-155).

Influenza A virus-IN-8 (S5), a macrocyclic peptide, exhibits no cytotoxicity and acts as a potent inhibitor of Influenza A Virus (IAV), demonstrating significant protease stability, with IC50 values of 6.7 nM for H1 and 6.6 nM for H5 variants. It has a high affinity for H1 variants, binding to a conserved region in the HA stem with a dissociation constant (Kd) of 1.0 nM [1].

Influenza HA (126-138) is a peptide derived from the hemagglutinin (HA) protein of the influenza virus, consisting of amino acids 126-138, and has the ability to induce apoptosis in both thymic and peripheral T-cells.

Influenza Matrix Protein (61-72) is a peptide derived from the matrix protein of influenza viruses, encompassing amino acids 61-72, and has the ability to elicit a CD4+ T-cell response.

PA (224-233), Influenza is a 10-aa peptide fragment of the polymerase 2 protein in the Influenza A virus.

This peptide is a H2-Db-restricted epitope from Influenza nucleoprotein (147-155).

CEF1, Influenza Matrix Protein M1 (58-66), is an epitope derived from the matrix protein of the influenza A virus. GILGFVFTL is an HLA-A2-restricted epitope from this matrix M1 protein.

HLA-B*08 restricted influenza virus nucleoprotein epitope.

Influenza HA (518-526) is an immunodominant epitope in H2d mice post flu virus infection.

Influenza Hemagglutinin is an HLA-DRB 0101-restricted epitope from influenza hemagglutinin (307-319).

CEF4 acetate (CEF4 acetate (199727-68-9 free base)) is a polypeptide corresponding to amino acid sequence 342-351 of the influenza A virus nucleocapsid protein.

CEF6 acetate is a HLA-B7 restricted influenza virus nucleoprotein epitope, belongs to the CEF control peptides. The CEF control peptides are 8-12 amino acids in length, with sequences derived from the human cytomegalovirus, Epstein-Barr virus and influenz

CEF3 acetate corresponds to aa 13-21 of the influenza A virus M1 protein. The matrix (M1) protein of influenza A virus is a multifunctional protein that plays essential structural and functional roles in the virus life cycle.

Influenza Hemagglutinin (HA) Peptide is a tag peptide derived from an epitope of the influenza hemagglutinin protein.

M2e, human, a vaccine candidate for human influenza A, encompasses the 23 extracellular residues of M2 (the third integral membrane protein of influenza A) and exhibits remarkable conservation across all strains, highlighting its potential as a broadly protective option.

M2e, the human Transmembrane Domain of M2 Protein (TFA), encompasses the 23 extracellular residues of M2, the third integral membrane protein of Influenza A, and exhibits remarkable conservation across all strains of human influenza A. This conservation positions M2e, human TFA as a promising and adaptable vaccine candidate capable of providing protection against all strains of human influenza A [1].

Defensin HNP-3 is a peptide secreted by human polymorphonuclear leukocytes (PMNs) that has antimicrobial properties. It induces lysis of mammalian cells when used at a concentration of 25 μg/mL. It also inhibits growth of E. faecalis (ED50 = 100 nM) and clinical isolates of P. aeruginosa (MIC90 = 4 μM). HNP-3 binds to recombinant HIV-1 envelope glycoprotein (gp120) and human CD4 (Kds = 52.8 and 34.9 nM, respectively). It also binds to recombinant, immobilized human surfactant protein D (SP-D; Kd = 55.7 nM) and inhibits focus formation in Madin-Darby canine kidney (MDCK) cells infected with influenza A virus (IAV).

CEF6, a HLA-B7 restricted influenza virus nucleoprotein epitope, belongs to the CEF control peptides. The CEF control peptides are 8-12 amino acids in length, with sequences derived from the human cytomegalovirus, Epstein-Barr virus and influenza virus.

CEF3 (SIIPSGPLK) is a peptide representing amino acids 13-21 of the M1 protein in the influenza A virus. The M1 protein is a versatile component of the influenza A virus, carrying out crucial structural and functional tasks throughout the virus's life cycle.

Retrocyclin-3 is an antimicrobial peptide exhibiting activity against human immunodeficiency virus (HIV), influenza A, and herpes simplex virus (HSV) [1].

Urumin, a compound with antiviral properties, inhibits human influenza A virus growth, particularly the PR8 strain, with an inhibitory concentration (IC 50) of 3.8 μM. It acts by targeting the conserved stalk of H1 hemagglutinin and can neutralize drug-resistant H1 influenza viruses. Additionally, Urumin offers protective effects against lethal influenza infection in naive mice [1].

CEF4 is a peptide derived from amino acids (aa) 342-351 of the influenza A virus nucleocapsid protein.

Retrocyclin-2 is an antimicrobial peptide effective against human immunodeficiency virus (HIV), influenza A, and herpes simplex virus (HSV) [1].

TAT-HA2 Fusion Peptide, a peptide-based delivery agent, synergizes the pH-sensitive HA2 fusion peptide from Influenza with the cell-penetrating peptide TAT from HIV. This compound facilitates the cellular uptake of macromolecules through the TAT component and triggers their release into cells by exploiting the acidifying endosomal lumen to induce membrane leakage via the HA2 component [1].

Polyaspartic acid, denoted as Asp-Asp-Asp-Asp-Asp-Asp, plays a crucial role in the specificity of catalytic and antigenic sites of influenza virus neuraminidase, which is determined by the presence of specific amino acids.

Asp-Asp-Asp-Asp-Asp-Asp TFA, a polyaspartic acid, influences the specificity of catalytic and antigenic sites in influenza virus neuraminidase through its unique amino acid composition.

Z-VRPR-FMK (TFA), a selective and irreversible inhibitor of Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), is a tetrapeptide shown to provide protection against influenza A virus (IAV) infection [1].